A 31 year-old man with Primary Mediastinal B-large Cell Lymphoma, involvement of intrathoracic, pericardial lymph nodes…

Cancer History:

First diagnosis of cancer: 08/2016 Primary mediastinal B-large cell lymphoma

Therapy received:

Surgery: Yes  05/12/2017 operation on the lung

Chemotherapy: 6x R-DA-EPOCH; 1x R-DHAP; 1x dexaBEAM; 1 x IGEV+ oxaliplatin

Immunotherapy: 2x nivolumab, lenalinomide. Others: No

Clinical Trial Number: NCT03125577; enrolled date: 28/06/2017

Interventions: 4SCART (CD19, CD30)

CRS Grade:0 ; other side effects: no

Treatment response: CR after nivolumab+lenalidomide

Quality of Life: improved

Progression-free interval: 1 year

Current status: PMBCL converted to HL, responded to treatment

Disease images before and after CART treatment (with time)

Link of published paper, youtube, patient’s feedback letter:

1）Chang LJ, Dong LJ, Zhu J. et al. (2015) 4SCAR19 Chimeric Antigen Receptor-Modified T Cells As a Breakthrough Therapy for Highly Chemotherapy-Resistant Late-Stage B Cell Lymphoma Patients with Bulky Tumor Mass. Blood 126 (23), 264.

2）Jing HM, Chang LJ, Chen MY, Bao F, Wang J, Wang WM, Liu YY, Kuo HH, Liu YC, Dong LJ. (2015) Up-Regulation of CAR-T Cells after G-CSF and Dexamethasone Treatment in a Defuse Large B Cell Lymphoma Patient Receiving 4SCAR19 T Cell Therapy. Blood 126 (23), 5130.

3）L-J Chang, Lujia D, Liu Y-C, Tsao S-T, Li Y-C, Liu L, Gao Z, Tan X, Lu D-P, Zhang J-P, Wang J-B, Ying Y-M, Zhang L-P, Zheng H, Wang K, Zheng X-L, Wang H-X, Lai X, and Li D (2016) Safety and Efficacy Evaluation of 4SCAR19 Chimeric Antigen Receptor-Modified T Cells Targeting B Cell Acute Lymphoblastic Leukemia - Three-Year Follow-up of a Multicenter Phase I/II Study. Blood 128 (22), 587.

4） Hao L, Li T, Chang L-J and Chen X. (2017) Adoptive immunotherapy for B-cell malignancies using CD19-targeted chimeric antigen receptor T cells: a systematic review of efficacy and safety. Curr Med Chem.

5）Chang, L.-J., Li, Y. Tu, S. et al. Phase I/II Trial of Multi-Target Chimeric Antigen Receptor Modified T Cells (4SCAR2.0) Against Relapsed or Refractory Lymphomas. (2018) Blood 132:225.